GA-68: Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
Study Details
Study Description
Brief Summary
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. Goals are to 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used to measure response to treatment. These studies will be obtained with the long term goal of submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and children.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. The goals are to 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used to measure response to treatment. These studies will be obtained with the long term goal of submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and children.
Project Design
68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors is a prospective, Phase 1-2, single center, open-label study in subjects with known or suspected somatostatin receptor positive tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study with an option to receive a second 68Ga-DOTATOC PET/CT if they begin a new treatment (surgery, hepatic embolization, Sandostatin LAR, chemotherapy, targeted biological therapy, or peptide receptor radiotherapy) within 30 days of the first scan. The second scan will be performed at a time recommended by the treating physician as optimal interval to observe results from treatment.
Project Goal
This study is planned to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide ([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of response to treatment in patients with Somatostatin receptor expressing tumors.
Neuroendocrine tumors are solid malignant tumors that arise from dispersed neuroendocrine cells found throughout the body. Gastroenteropancreatic neuroendocrine tumors (NETs) can be divided into two groups: Carcinoid tumors that may arise from the lungs, stomach, small bowel or colon and pancreatic neuroendocrine tumors (also known as pancreatic islet cell tumors). The clinical behavior of NETs is extremely variable; some may cause hormone hypersecretion and others may not, the majority of them are slow-growing tumors (well-differentiated NETs), whereas some NETs are highly aggressive (poorly differentiated NETs). The incidence of NETs is increasing, from 1.1/100,000 per year in 1973 to 5.3/100,000 per year in 20041. Among NETs, 25% have distant metastases and 25% have regional involvement at the time of initial diagnosis[1]. Other tumors that express high levels of somatostatin receptors include neuroblastoma, medulloblastoma, and Ewing's sarcoma[2-4].
The radiological detection and staging of these tumors is challenging and requires a multimodality approach. Somatostatin receptor imaging with In-111 Pentetreotide (OctreoScan) and multiphase CT are the most commonly used modalities although the use of endoscopic ultrasound and MRI is also increasing. Surgery is the only curative option for NETs. However, curative surgery in malignant NET is possible in less than 30% of patients with recurrence identified in the majority of patients as late as 15 years after initial surgery. Treatment with somatostatin analogs, which include the short acting subcutaneous and long acting release (LAR) octreotide, are effective in stabilizing NETs and have been recently demonstrated to prolong the time to progression of disease[5]. Chemotherapy is generally not effective in low grade NETs, but it may be helpful in high grade and pancreatic NETs. On the other hand, neuroblastoma, medulloblastoma, and Ewing's sarcoma are initially responsive to chemotherapy, but relapses are common and salvage therapies are not very effective, resulting in <30% overall survival at 5 years[6-8].
Somatostatin Receptor Targeted Imaging and Therapy
Tumors that express somatostatin receptors can be targeted with radiolabeled somatostatin analogues for imaging and treatment. Somatostatin receptor gamma camera imaging with In-111 DTPA-octreotide (OctreoScan) targeting somatostatin receptor 2 (sstr2), is used routinely for imaging of neuroendocrine tumors with a detection rate >90% for well-differentiated carcinoid tumors and majority of pancreatic NETs, but only a 50% detection rate for insulinomas, which may show a weaker expression of sstr2[9].
Given the clinical efficacy of this radiolabeled peptide as a diagnostic agent, studies to test if therapeutic radiation could be targeted to tumors in a similar manner was a logical next step. Attempts to utilize In-111 DTPA Octreotide as a therapeutic agent have been minimally effective due to short range of auger electrons utilized in this therapy. The efficacy of this treatment was improved with the development of somatostatin analogues labeled with beta emitting radioisotopes. Further studies have identified DOTA as a superior chelator compared to DTPA, increasing the stability and receptor targeting of somatostatin analogues[10]. There is now a large clinical experience with Yttrium-90 DOTA-tyr3-Octreotide peptide radioreceptor therapy (PRRT) in Europe, primarily in adults with neuroendocrine tumors[11]. An international Phase II clinical trial then followed and included several trial sites in the United States, notably the University of Iowa, where we entered 40 subjects[12]. With its low toxicity profile, the significant improvement in symptoms and quality of life and the lack of effective alternative therapies, PRRT has been suggested as possible first-line therapy in adult patients with gastroenteropancreatic neuroendocrine tumor. Recent data have also demonstrated a significant survival benefit with PRRT compared to historical controls in this population. We have also now conducted a Phase I trial of 90Y-DOTA-tyr3-Octreotide in children and young adults at the University of Iowa, which also shows promise of efficacy of this treatment in pediatric patient population[13]. We now propose a new imaging agent for use in diagnosis and therapy of Somatostatin receptor positive tumors.
Somatostatin Receptor PET Imaging with Ga-68 DOTA0-Tyr3-octreotide
More recently, positron emission tomography (PET) radiopharmaceuticals have been developed that can be labeled with Gallium-68 (Ga-68). Gallium-68 is a generator product with a half-life of 68 min (compared to 67 hours for In-111 in OctreoScan). The parent nuclide of Ga-68 is Germanium-68, which has a half-life of 270.8 days. Ga-68 decays by 89% through positron emission and 11% by electron capture. Its parent, A number of Ga-68 DOTA-conjugated peptides have been introduced, including Ga-68 DOTA0-Tyr3]octreotide (Ga-68 DOTATOC), Ga-68 DOTA0-1NaI3-octreotide (Ga-68 DOTANOC) and [Ga-68 DOTA0-Tyr3]octreotate (Ga-68 DOTATOC). All of these radiolabeled peptides bind to sstr2, although DOTANOC also binds to sstr 3 and sstr 5, and DOTATOC to sstr5[14]. The primary advantage of Ga-68 based somatostatin receptor PET imaging over OctreoScan SPECT is the higher imaging resolution and accurate quantitation of uptake due to robust attenuation correction. The improved resolution and quantitation of uptake obtained with Ga-68 DOTATOC PET should provide a more accurate assessment of somatostatin receptor density, which will lead to a more accurate prediction of treatment response to somatostatin analogues. A recent study from Europe comparing Ga-68 DOTATOC with Octreoscan found Ga-68 DOTATOC to be superior in detection of skeletal and pulmonary involvement of neuroendocrine tumors[15].
Rationale and overall study design
Rationale:68Ga-DOTATOC positron emission tomography (PET) scanning and 90Y-DOTATOC peptide receptor radionuclide therapy (PRRT) are readily available in Europe, but neither radiopharmaceutical is approved for use in the United States. IND #61,907 is currently active under the above named investigators for 90Y-DOTATOC PRRT in somatostatin receptor positive tumors. These investigators have conducted a single institution Phase I trial of 90Y-DOTATOC therapy in children and young adults (Appendix I) and have participated in a Phase II trial of 90Y-DOTATOC PRRT in adults (also in Appendix II).
The purpose of this amendment to the IND application is to test the efficacy of 68Gallium-DOTATOC in diagnosis, staging, and determination of response to 90Y-DOTATOC PRRT in children and adults with known or suspected somatostatin receptor positive tumors, including, but not limited to neuroendocrine tumors, neuroblastoma, and medulloblastoma. 68Ga-DOTATOC PET would replace 111In-DTPA-Octreotide single photon emission tomography (SPECT) imaging. Whereas, Octreoscan uses a 222 MBq imaging dose of Indium (2.8 day half life) resulting in an effective dose equivalent (HE) equal to 2.61 rads, [68Ga]DOTATOC (68 min half life) uses 185 MBq with an effective dose equivalent of 0.46 rads. In addition, [68Ga]DOTATOC PET/CT can be completed within 2 hours compared to an Octreoscan which requires 3 visits over 24 hours, making [68Ga]DOTATOC a much more convenient imaging choice for patients. The data obtained in this Ga-68 DOTATOC PET study will be used to support the use of 68Ga-DOTATOC PET for diagnosis and staging in patients with suspected or proven somatostatin receptor positive tumors.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 68Ga-DOTATOC PET/CT 68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors |
Drug: 68Ga-DOTATOC PET/CT
1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent [During PET scan and 24 hours post scan]
Subject receives an injection of 68Ga-DOTATOC, a somatostatin-like peptide that binds to somatostatin receptor and is tagged with a radionuclide that can be detected by positron emission tomography (PET). Whole body PET is performed; patient is queried regarding any adverse events immediately and again 24 hrs after completion of scan read by certified nuclear medicine physician to determine if any known tumor lesions take up 68Ga-DOTATOC.Severity of adverse events will be graded according to NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Adverse events are assessed immediately after PET scan and 24 hrs after completion of the scan.
- Number of Subjects With Adverse Events Related to the Use of the 68Ga-DOTATOC [Up to 6 months]
Number of subjects with adverse events related to the use of the 68Ga-DOTATOC radiopharmaceutical in accordance with National Cancer Institute (NCI) toxicity guidelines (NCI Common Terminology Criteria for Adverse Events version 4.0)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed informed consent
-
Age greater than or equal to 2 years
-
Known or suspected somatostatin receptor positive tumor such as carcinoid; neuroendocrine tumor; neuroblastoma; medulloblastoma; pheochromocytoma. Supporting evidence may include MRI, CT, biochemical markers, and or pathology report.
-
Karnofsky performance status or Lansky Play Scale status of greater than 50 (or ECOG/WHO equivalent)
-
Subject is male; or is a female who is either pre-menarchal, surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (> 1 years without menses), non-lactating, or of childbearing potential for whom a serum pregnancy test (with the results known prior to investigational product administration) is negative. A negative serum pregnancy test will be required for all female subjects with child bearing potential. If a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is capable of becoming pregnant.
Exclusion Criteria:
-
Subject weighs more than 400 pounds (Subjects who weigh more than 400 pounds will not be able to fit inside the imaging machines).
-
Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.)
-
Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
-
Does the subject have any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance?
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Iowa Health Care | Iowa City | Iowa | United States | 52242 |
Sponsors and Collaborators
- Sue O'Dorisio
Investigators
- Principal Investigator: Sue O'Dorisio, MD, University of Iowa
Study Documents (Full-Text)
More Information
Publications
None provided.- 201110718
- 114398
Study Results
Participant Flow
| Recruitment Details | Participants were recruited from the University of Iowa Holden Comprehensive Cancer Center Clinics and University of Iowa Children's Hospital. Participants being seen for known or suspected somatostatin receptor positive tumors were recruited for the study. Malignancies included neuroblastoma, medulloblastoma, and pheochromocytoma. |
|---|---|
| Pre-assignment Detail | Female subjects of childbearing potential were given a pregnancy test (serum) prior to receiving research-related radiation. A women who was pregnant could not participate in the study. |
| Arm/Group Title | 68Ga-DOTATOC PET/CT |
|---|---|
| Arm/Group Description | 68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors 68Ga-DOTATOC PET/C: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV. |
| Period Title: Overall Study | |
| STARTED | 223 |
| COMPLETED | 219 |
| NOT COMPLETED | 4 |
Baseline Characteristics
| Arm/Group Title | 68Ga-DOTATOC PET/CT |
|---|---|
| Arm/Group Description | 68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors 68Ga-DOTATOC PET/C: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV. |
| Overall Participants | 223 |
| Age (Count of Participants) | |
| <=18 years |
9
4%
|
| Between 18 and 65 years |
32
14.3%
|
| >=65 years |
182
81.6%
|
| Age (years) [Mean (Full Range) ] | |
| Mean (Full Range) [years] |
53
|
| Sex: Female, Male (Count of Participants) | |
| Female |
136
61%
|
| Male |
87
39%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |
| Hispanic or Latino |
5
2.2%
|
| Not Hispanic or Latino |
215
96.4%
|
| Unknown or Not Reported |
3
1.3%
|
| Race (NIH/OMB) (Count of Participants) | |
| American Indian or Alaska Native |
1
0.4%
|
| Asian |
2
0.9%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
| Black or African American |
2
0.9%
|
| White |
209
93.7%
|
| More than one race |
1
0.4%
|
| Unknown or Not Reported |
8
3.6%
|
| Region of Enrollment (participants) [Number] | |
| United States |
223
100%
|
Outcome Measures
| Title | To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent |
|---|---|
| Description | Subject receives an injection of 68Ga-DOTATOC, a somatostatin-like peptide that binds to somatostatin receptor and is tagged with a radionuclide that can be detected by positron emission tomography (PET). Whole body PET is performed; patient is queried regarding any adverse events immediately and again 24 hrs after completion of scan read by certified nuclear medicine physician to determine if any known tumor lesions take up 68Ga-DOTATOC.Severity of adverse events will be graded according to NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Adverse events are assessed immediately after PET scan and 24 hrs after completion of the scan. |
| Time Frame | During PET scan and 24 hours post scan |
Outcome Measure Data
| Analysis Population Description |
|---|
| Subjects who reported an adverse event and relationship of adverse event to study drug (68Ga-DOTATOC). Several subjects reported more than one adverse event; thus, the number of subjects who experienced an event will be less than the number of events. |
| Arm/Group Title | 68Ga-DOTATOC PET/CT |
|---|---|
| Arm/Group Description | 68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors 68Ga-DOTATOC PET/C: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV. |
| Measure Participants | 105 |
| Possibly related |
18
|
| Probably related |
1
|
| Unlikely related |
6
|
| Unrelated |
157
|
| Title | Number of Subjects With Adverse Events Related to the Use of the 68Ga-DOTATOC |
|---|---|
| Description | Number of subjects with adverse events related to the use of the 68Ga-DOTATOC radiopharmaceutical in accordance with National Cancer Institute (NCI) toxicity guidelines (NCI Common Terminology Criteria for Adverse Events version 4.0) |
| Time Frame | Up to 6 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | 68Ga-DOTATOC PET/CT |
|---|---|
| Arm/Group Description | 68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors 68Ga-DOTATOC PET/CT: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV. |
| Measure Participants | 223 |
| Number of subjects with no adverse events (AE) |
118
52.9%
|
| Number of subjects with Grade 1 or 2 AE |
101
45.3%
|
| Number of subjects with Grade 3 AE |
4
1.8%
|
| Number of subjects with Grade 4 or 5 AE |
0
0%
|
Adverse Events
| Time Frame | From time of study drug injection, through PET scan up to 24 hours post injection. | |
|---|---|---|
| Adverse Event Reporting Description | ||
| Arm/Group Title | 68Ga-DOTATOC PET/CT | |
| Arm/Group Description | 68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors 68Ga-DOTATOC PET/C: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV. | |
All Cause Mortality |
||
| 68Ga-DOTATOC PET/CT | ||
| Affected / at Risk (%) | # Events | |
| Total | 2/223 (0.9%) | |
Serious Adverse Events |
||
| 68Ga-DOTATOC PET/CT | ||
| Affected / at Risk (%) | # Events | |
| Total | 1/223 (0.4%) | |
| Gastrointestinal disorders | ||
| Nausea | 1/223 (0.4%) | 1 |
| General disorders | ||
| Pain NOS | 1/223 (0.4%) | 1 |
| Musculoskeletal and connective tissue disorders | ||
| Muscle weakness, generalized of specific area (not due to neuropathy - Whole body/generalized | 1/223 (0.4%) | 1 |
Other (Not Including Serious) Adverse Events |
||
| 68Ga-DOTATOC PET/CT | ||
| Affected / at Risk (%) | # Events | |
| Total | 176/223 (78.9%) | |
| Blood and lymphatic system disorders | ||
| Edema: limb | 2/223 (0.9%) | 2 |
| Cardiac disorders | ||
| Cardiac General - Other (Specify, __) | 1/223 (0.4%) | 1 |
| Eye disorders | ||
| Ocular/Visual - Other (Specify, __) | 1/223 (0.4%) | 1 |
| Vision-blurred vision | 2/223 (0.9%) | 2 |
| Vision-flashing lights/floaters | 1/223 (0.4%) | 1 |
| Gastrointestinal disorders | ||
| Constipation | 2/223 (0.9%) | 2 |
| Diarrhea | 15/223 (6.7%) | 15 |
| Distension/bloating, abdominal | 1/223 (0.4%) | 1 |
| Nausea | 13/223 (5.8%) | 13 |
| Vomiting | 4/223 (1.8%) | 5 |
| General disorders | ||
| Fatigue (asthenia, lethargy, malaise) | 3/223 (1.3%) | 3 |
| Sweating (diaphoresis) | 7/223 (3.1%) | 7 |
| Gastrointestinal - Other (Specify, __) | 1/223 (0.4%) | 1 |
| Pain - Other (Specify, __) | 1/223 (0.4%) | 1 |
| Hepatobiliary disorders | ||
| Hemoglobin | 12/223 (5.4%) | 12 |
| Leukocytes (total WBC) | 4/223 (1.8%) | 4 |
| Lymphopenia | 11/223 (4.9%) | 11 |
| Platelets | 2/223 (0.9%) | 2 |
| Infections and infestations | ||
| Infection - Other (Specify, __) | 1/223 (0.4%) | 1 |
| Metabolism and nutrition disorders | ||
| ALT, SGPT (serum glutamic pyruvic transaminase) | 7/223 (3.1%) | 7 |
| AST, SGOT(serum glutamic oxaloacetic transaminase) | 13/223 (5.8%) | 13 |
| Bilirubin (hyperbilirubinemia) | 3/223 (1.3%) | 3 |
| Creatinine | 5/223 (2.2%) | 5 |
| Musculoskeletal and connective tissue disorders | ||
| Arthritis (non-septic) | 1/223 (0.4%) | 1 |
| Muscle weakness, generalized or specific area (not due to neuropathy) - Extremity-upper | 1/223 (0.4%) | 1 |
| Muscle weakness, generalized or specific area (not due to neuropathy) - Whole body/generalized | 1/223 (0.4%) | 1 |
| Pain - Abdomen NOS | 11/223 (4.9%) | 13 |
| Pain - Back | 6/223 (2.7%) | 6 |
| Pain - Chest wall | 3/223 (1.3%) | 3 |
| Pain - Extremity-limb | 7/223 (3.1%) | 7 |
| Pain - Joint | 2/223 (0.9%) | 2 |
| Pain - Throat/pharynx/larynx | 1/223 (0.4%) | 1 |
| Pain-neck | 2/223 (0.9%) | 2 |
| Nervous system disorders | ||
| Cognitive disturbance | 1/223 (0.4%) | 1 |
| Dizziness | 1/223 (0.4%) | 1 |
| Neurology - Other (Specify, __) | 1/223 (0.4%) | 1 |
| Neuropathy: sensory | 5/223 (2.2%) | 5 |
| Pain - Head/headache | 4/223 (1.8%) | 4 |
| Reproductive system and breast disorders | ||
| Sexual/Reproductive Function - Other (Specify, __) | 1/223 (0.4%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||
| Dyspnea (shortness of breath) | 3/223 (1.3%) | 3 |
| Skin and subcutaneous tissue disorders | ||
| Dermatology/Skin - Other (Specify, __) | 3/223 (1.3%) | 3 |
| Flushing | 6/223 (2.7%) | 6 |
| Injection site reaction/extravasation changes | 1/223 (0.4%) | 1 |
| Pruritus/itching | 5/223 (2.2%) | 5 |
| Urticaria (hives, welts, wheals) | 1/223 (0.4%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Sue O'Dorisio, MD, PhD |
|---|---|
| Organization | University of Iowa Holden Comprehensive Cancer Center |
| Phone | 319-356-7873 |
| sue-odorisio@uiowa.edu |
- 201110718
- 114398